Boston Scientific Corp. traded higher on Wednesday after posting better-than-expected second-quarter results and raising its full-year outlook, according to Benzinga. The medical technology giant reported second-quarter revenue of $5.06 billion, exceeding the $4.89 billion consensus estimate. Adjusted earnings reached 75 cents per share, topping both analyst and internal guidance. CEO Mike Mahoney said the quarter delivered strong revenue growth, margin expansion, and continued investment in future growth.
